The United Therapeutics Corp. (UTHR) PT Set at $144.00 by Cowen and Company

The United Therapeutics Corp. (UTHR) PT Set at $144.00 by Cowen and Company

United Therapeutics Corp. (NASDAQ:UTHR) has been given a $144.00 price objective by equities researchers at Cowen and Company in a report issued on Thursday. The brokerage presently has a a “buy” rating on the biotechnology company’s stock. Cowen and Company’s target price suggests a potential upside of 21.89% from the stock’s previous close.

A number of other equities research analysts have also recently commented on UTHR. Zacks Investment Research cut shares of United Therapeutics Corp. from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 8th. HC Wainwright reissued a “hold” rating on shares of United Therapeutics Corp. in a research report on Friday, July 29th. Ladenburg Thalmann raised shares of United Therapeutics Corp. from a “neutral” rating to a “buy” rating and increased their target price for the company from $128.00 to $138.00 in a research report on Friday. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating for the company in a research report on Friday, July 29th. Finally, Jefferies Group reissued a “hold” rating and set a $120.00 target price on shares of United Therapeutics Corp. in a research report on Friday, July 29th. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $137.17.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) opened at 118.14 on Thursday. The firm has a 50-day moving average of $119.58 and a 200-day moving average of $116.21. The company has a market cap of $5.01 billion, a P/E ratio of 8.00 and a beta of 1.42. United Therapeutics Corp. has a 52-week low of $97.52 and a 52-week high of $164.04.

United Therapeutics Corp. (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, October 27th. The biotechnology company reported $4.36 earnings per share for the quarter, topping the consensus estimate of $3.38 by $0.98. United Therapeutics Corp. had a net margin of 44.40% and a return on equity of 42.62%. The firm earned $408.20 million during the quarter, compared to analysts’ expectations of $400.58 million. During the same quarter in the prior year, the company earned $3.55 EPS. The company’s revenue was up 5.7% compared to the same quarter last year. Equities research analysts forecast that United Therapeutics Corp. will post $15.95 earnings per share for the current year.

In other United Therapeutics Corp. news, Director Christopher Patusky sold 5,000 shares of the stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $122.73, for a total transaction of $613,650.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $613,650. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Tommy G. Thompson sold 1,291 shares of the stock in a transaction on Monday, September 26th. The shares were sold at an average price of $125.57, for a total transaction of $162,110.87. Following the transaction, the director now directly owns 1,291 shares in the company, valued at $162,110.87. The disclosure for this sale can be found here. 7.50% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the stock. State Street Corp increased its position in United Therapeutics Corp. by 6.1% in the first quarter. State Street Corp now owns 1,846,710 shares of the biotechnology company’s stock valued at $205,778,000 after buying an additional 105,824 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in United Therapeutics Corp. by 7.3% in the first quarter. UBS Asset Management Americas Inc. now owns 226,285 shares of the biotechnology company’s stock valued at $25,215,000 after buying an additional 15,402 shares during the last quarter. Riverhead Capital Management LLC increased its position in United Therapeutics Corp. by 134.2% in the first quarter. Riverhead Capital Management LLC now owns 60,875 shares of the biotechnology company’s stock valued at $6,783,000 after buying an additional 34,883 shares during the last quarter. Geode Capital Management LLC increased its position in United Therapeutics Corp. by 21.1% in the first quarter. Geode Capital Management LLC now owns 455,719 shares of the biotechnology company’s stock valued at $50,761,000 after buying an additional 79,502 shares during the last quarter. Finally, Hancock Holding Co. increased its position in United Therapeutics Corp. by 12.1% in the first quarter. Hancock Holding Co. now owns 5,277 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 568 shares during the last quarter.

About United Therapeutics Corp.

Related posts

Leave a Comment